SVB Securities analyst Joseph Schwartz reiterated a Buy rating on PepGen Inc. (PEPG – Research Report) on December 7. The company’s shares closed yesterday at $13.91.
According to TipRanks, Schwartz is an analyst with an average return of -18.4% and a 32.76% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Ascendis Pharma, and Amicus.
The analyst consensus on PepGen Inc. is currently a Moderate Buy rating.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $17.81 and a one-year low of $4.32. Currently, PepGen Inc. has an average volume of 302K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases.
Read More on PEPG:
